A
AVEO

Abingworth’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Abingworth’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40,000
Closed -$1.32M – 17
2018
Q3 		$1.32M Hold
40,000
– – 0.78% 14
2018
Q2 		$900K Buy
+40,000
New +$948K 0.51% 16

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Abingworth's AVEO Position: Q4 2018 in Review

Abingworth sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2018, closing a stake of 40,000 shares — an estimated $1.32M sold.

Abingworth first reported a position in AVEO in Q2 2018 and held it in 2 quarters. The position peaked at $1.32M in Q3 2018. 99 funds tracked by Wall St. Rank hold AVEO as of Q4 2018.

  • Abingworth reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Abingworth sold 40,000 AVEO Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1.32M.
  • Abingworth first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
  • Abingworth's AVEO Pharmaceuticals, Inc. position peaked at $1.32M in Q3 2018.
  • 99 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2018.

Based on Abingworth's 13F filing for Q4 2018, filed 14 Feb 2019.